Clinical trial

The efficacy and safety of oral PF-03491390, a pancaspase inhibitor - A randomized placebo-controlled study in patients with chronic hepatitis C

M. L. Shiffman, P. Pockros, J. G. McHutchison, Eugene R Schiff, M. Morris, G. Burgess

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Background Elevated serum levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) reflect hepatocellular injury in patients with chronic hepatitis C virus (HCV). Increased apoptosis and activated caspases are present in these patients. PF-03491390 inhibits multiple caspases and lowers serum AST and ALT levels in patients with chronic liver diseases. Aim To determine if treatment with an oral pancaspase inhibitor could reduce serum AST and ALT in patients with HCV. Methods Double-blind, randomized, placebo-controlled, parallel-dose study in 204 patients treated with placebo or PF-03491390 (5, 25 or 50 mg) orally twice daily (b.d.) for up to 12 weeks. Serum AST and ALT were monitored weekly. Results Significant reductions in serum AST and ALT were observed within 1 week of initiating PF-03491390 in all treatment groups (P < 0.0001). These reductions in AST and ALT were maintained throughout the 12 week treatment period and returned to baseline levels when PF-03491390 was discontinued. Increasing the dose did not further lower AST or ALT. The most frequently reported adverse events were headache and fatigue. Conclusion PF-03491390 significantly reduced serum AST and ALT levels in patients with chronic HCV, and was well tolerated over 12 weeks.

Original languageEnglish
Pages (from-to)969-978
Number of pages10
JournalAlimentary Pharmacology and Therapeutics
Volume31
Issue number9
DOIs
StatePublished - May 1 2010

Fingerprint

Chronic Hepatitis C
Aspartate Aminotransferases
Alanine Transaminase
Placebos
Clinical Trials
Safety
Serum
Hepacivirus
Caspases
3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
Double-Blind Method
Fatigue
Headache
Liver Diseases
Chronic Disease
Therapeutics
Apoptosis
Wounds and Injuries

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Clinical trial : The efficacy and safety of oral PF-03491390, a pancaspase inhibitor - A randomized placebo-controlled study in patients with chronic hepatitis C. / Shiffman, M. L.; Pockros, P.; McHutchison, J. G.; Schiff, Eugene R; Morris, M.; Burgess, G.

In: Alimentary Pharmacology and Therapeutics, Vol. 31, No. 9, 01.05.2010, p. 969-978.

Research output: Contribution to journalArticle

@article{6d5b5cb1a07846d1b63cb5bc76663890,
title = "Clinical trial: The efficacy and safety of oral PF-03491390, a pancaspase inhibitor - A randomized placebo-controlled study in patients with chronic hepatitis C",
abstract = "Background Elevated serum levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) reflect hepatocellular injury in patients with chronic hepatitis C virus (HCV). Increased apoptosis and activated caspases are present in these patients. PF-03491390 inhibits multiple caspases and lowers serum AST and ALT levels in patients with chronic liver diseases. Aim To determine if treatment with an oral pancaspase inhibitor could reduce serum AST and ALT in patients with HCV. Methods Double-blind, randomized, placebo-controlled, parallel-dose study in 204 patients treated with placebo or PF-03491390 (5, 25 or 50 mg) orally twice daily (b.d.) for up to 12 weeks. Serum AST and ALT were monitored weekly. Results Significant reductions in serum AST and ALT were observed within 1 week of initiating PF-03491390 in all treatment groups (P < 0.0001). These reductions in AST and ALT were maintained throughout the 12 week treatment period and returned to baseline levels when PF-03491390 was discontinued. Increasing the dose did not further lower AST or ALT. The most frequently reported adverse events were headache and fatigue. Conclusion PF-03491390 significantly reduced serum AST and ALT levels in patients with chronic HCV, and was well tolerated over 12 weeks.",
author = "Shiffman, {M. L.} and P. Pockros and McHutchison, {J. G.} and Schiff, {Eugene R} and M. Morris and G. Burgess",
year = "2010",
month = "5",
day = "1",
doi = "10.1111/j.1365-2036.2010.04264.x",
language = "English",
volume = "31",
pages = "969--978",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Clinical trial

T2 - The efficacy and safety of oral PF-03491390, a pancaspase inhibitor - A randomized placebo-controlled study in patients with chronic hepatitis C

AU - Shiffman, M. L.

AU - Pockros, P.

AU - McHutchison, J. G.

AU - Schiff, Eugene R

AU - Morris, M.

AU - Burgess, G.

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Background Elevated serum levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) reflect hepatocellular injury in patients with chronic hepatitis C virus (HCV). Increased apoptosis and activated caspases are present in these patients. PF-03491390 inhibits multiple caspases and lowers serum AST and ALT levels in patients with chronic liver diseases. Aim To determine if treatment with an oral pancaspase inhibitor could reduce serum AST and ALT in patients with HCV. Methods Double-blind, randomized, placebo-controlled, parallel-dose study in 204 patients treated with placebo or PF-03491390 (5, 25 or 50 mg) orally twice daily (b.d.) for up to 12 weeks. Serum AST and ALT were monitored weekly. Results Significant reductions in serum AST and ALT were observed within 1 week of initiating PF-03491390 in all treatment groups (P < 0.0001). These reductions in AST and ALT were maintained throughout the 12 week treatment period and returned to baseline levels when PF-03491390 was discontinued. Increasing the dose did not further lower AST or ALT. The most frequently reported adverse events were headache and fatigue. Conclusion PF-03491390 significantly reduced serum AST and ALT levels in patients with chronic HCV, and was well tolerated over 12 weeks.

AB - Background Elevated serum levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) reflect hepatocellular injury in patients with chronic hepatitis C virus (HCV). Increased apoptosis and activated caspases are present in these patients. PF-03491390 inhibits multiple caspases and lowers serum AST and ALT levels in patients with chronic liver diseases. Aim To determine if treatment with an oral pancaspase inhibitor could reduce serum AST and ALT in patients with HCV. Methods Double-blind, randomized, placebo-controlled, parallel-dose study in 204 patients treated with placebo or PF-03491390 (5, 25 or 50 mg) orally twice daily (b.d.) for up to 12 weeks. Serum AST and ALT were monitored weekly. Results Significant reductions in serum AST and ALT were observed within 1 week of initiating PF-03491390 in all treatment groups (P < 0.0001). These reductions in AST and ALT were maintained throughout the 12 week treatment period and returned to baseline levels when PF-03491390 was discontinued. Increasing the dose did not further lower AST or ALT. The most frequently reported adverse events were headache and fatigue. Conclusion PF-03491390 significantly reduced serum AST and ALT levels in patients with chronic HCV, and was well tolerated over 12 weeks.

UR - http://www.scopus.com/inward/record.url?scp=77950591438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950591438&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2010.04264.x

DO - 10.1111/j.1365-2036.2010.04264.x

M3 - Article

VL - 31

SP - 969

EP - 978

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 9

ER -